GCP
KPTI icon

GSA Capital Partners’s Karyopharm Therapeutics KPTI Stock Holding History

GSA Capital Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,076
Closed -$92K – 1894
2025
Q3 		$92K Buy
14,076
+182
+1% +$979 0.01% 1532
2025
Q2 		$60K Buy
+13,894
New +$68.2K ﹤0.01% 1651
2025
Q1 		– Sell
-106,562
Closed -$1.08M – 1877
2024
Q4 		$1.08M Sell
106,562
-11,818
-10% -$143K 0.08% 360
2024
Q3 		$1.47M Buy
118,380
+52,819
+81% +$656K 0.11% 228
2024
Q2 		$853K Sell
65,561
-21,049
-24% -$349K 0.06% 611
2024
Q1 		$1.96M Sell
86,610
-69,256
-44% -$1.21M 0.16% 112
2023
Q4 		$2.02M Buy
155,866
+117,979
+311% +$1.59M 0.17% 114
2023
Q3 		$762K Buy
+37,887
New +$850K 0.07% 543
2023
Q1 		– Sell
-5,477
Closed -$279K – 1707
2022
Q4 		$279K Buy
+5,477
New +$380K 0.03% 978
2022
Q1 		– Sell
-12,798
Closed -$1.23M – 1626
2021
Q4 		$1.23M Buy
12,798
+998
+8% +$99.5K 0.16% 131
2021
Q3 		$1.03M Buy
11,800
+9,857
+507% +$1.02M 0.1% 301
2021
Q2 		$301K Sell
1,943
-96
-5% -$13.9K 0.03% 944
2021
Q1 		$322K Buy
2,039
+579
+40% +$122K 0.05% 597
2020
Q4 		$339K Buy
+1,460
New +$338K 0.06% 672

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

GSA Capital Partners's KPTI Position: Q4 2025 in Review

GSA Capital Partners sold out of Karyopharm Therapeutics (KPTI) in Q4 2025, closing a stake of 14,076 shares — an estimated $92K sold.

GSA Capital Partners first reported a position in KPTI in Q4 2020 and held it in 14 quarters. The position peaked at $2.02M in Q4 2023. 69 funds tracked by Wall St. Rank hold KPTI as of Q4 2025.

  • GSA Capital Partners reported no remaining Karyopharm Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 14,076 Karyopharm Therapeutics shares in Q4 2025, an estimated $92K.
  • GSA Capital Partners first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 14 quarters.
  • GSA Capital Partners's Karyopharm Therapeutics position peaked at $2.02M in Q4 2023.
  • 69 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.